Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression.
Cytometry
Immuno-oncology
Lymphocytes
Phenotyping
Journal
SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
pubmed:
22
1
2022
medline:
4
5
2022
entrez:
21
1
2022
Statut:
ppublish
Résumé
The field of Immuno-Oncology (IO) is evolving to utilise novel antibody backbones that can co-target multiple cell-surface stimulatory and inhibitory co-receptors (SICR). This approach necessitates a better understanding of SICR co-expression at the single-cell level on IO-relevant tumor-infiltrating leukocyte (TIL) cell types such as T and natural killer (NK) cells. Using high-dimensional flow cytometry we established a comprehensive SICR profile for tumor-resident T and NK cells across a range of human solid tumors where there is a clear need for improved immunotherapeutic intervention. Leveraging the power of our large flow panel, we performed deep-phenotyping of the critical CD8
Identifiants
pubmed: 35058180
pii: S2472-5552(21)00020-4
doi: 10.1016/j.slasd.2021.12.001
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-106Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interests James Hair reports a relationship with AstraZeneca PLC that includes: employment and equity or stocks. Matthew J Robinson reports a relationship with AstraZeneca PLC that includes: employment and equity or stocks. Robert W Wilkinson reports a relationship with AstraZeneca PLC that includes: employment and equity or stocks. Simon J Dovedi reports a relationship with AstraZeneca PLC that includes: employment and equity or stocks.